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ABSTRACT
Malignant pleural mesothelioma causes the greatest
societal burden of all the asbestos-related diseases.
Progress in better understanding tumour biology will be
facilitated by the availability of quality-assured annotated
tissue. MesobanK has been created to establish a
bioresource of pleural mesothelioma tissue linked to
detailed anonymised clinical data. When complete, the
bioresource will comprise a 750-patient tissue microarray
and prospectively collected tissue, blood and pleural ﬂuid
from 300 patients with mesothelioma. Twenty-six new
cell lines have also been developed. MesobanK meets all
appropriate ethical and regulatory procedures and has
recently opened to requests for tissue and data.
BACKGROUND
The UK has the highest incidence of asbestos-
related disease per head of population in the world.
Of the various asbestos-related diseases, malignant
pleural mesothelioma (MPM) imposes the greatest
societal burden. Despite the import of asbestos into
the UK having been banned for two decades,
Health and Safety Executive data for 2012 shows
that MPM caused 2535 deaths in England, Wales
and Scotland.1 This is a legacy of the latency
period from exposure to disease of up to 50 years.
While cases of MPM in Western Europe and North
America should begin to fall over the next 30–
40 years, the use of asbestos in Asia, South America
and states of the former Soviet Union is increasing
and it is believed that some 125 million people glo-
bally are exposed in the workplace.2 Therefore,
lessons learnt about MPM will have a major impact
on global health for decades to come.
Until recently there has been a relative paucity of
basic and translational research into MPM, but it is
now widely accepted that progress in diagnosis and
treatment is only likely to be achieved with a better
understanding of tumour biology. As with many
other rare cancers, the fundamental mechanisms
regulating the processes underpinning cell growth
and death in MPM are poorly understood owing to
a lack of appropriate high-quality clinical samples.
Such research will be facilitated by the availability
of quality-assured annotated tissue.
Although there are several mesothelioma tissue
collections in various countries, most operate as
‘virtual’ collections of tissue rather than as a centra-
lised collection. This means that rather than being
held in a central location, samples are stored in a
variety of institutions under non-standardised con-
ditions having been collected to differing operating
policies. Similarly, although a few UK-based clin-
ical/research groups hold fresh tissue from small
numbers of patients with MPM, these collections
are not formally linked and do not involve the col-
lection of tissue and data in accordance with any
universal standard operating procedures (SOPs).
MesobanK UK (http://www.mesobank.com) has
been established through funding from the British
Lung Foundation (BLF) and the Mick Knighton
Mesothelioma Research Fund as a result of a BLF/
National Cancer Research Institute call for a biore-
source to underpin research into asbestos-related
disease.3
The overall goal of MesobanK is to provide a
framework for the systematic collection, curation
and quality assurance of well-annotated mesotheli-
oma tissue that will facilitate high-quality basic
science, translational and clinical research into
mesothelioma.
The objectives are to:
A. Establish a bioresource of MPM tissue and
blood linked to a detailed clinical database.
B. Develop novel annotated mesothelioma cell
lines.
C. Put in place a web-based information technol-
ogy infrastructure for annotating and searching
the bioresource.
D. Develop a robust infrastructure to allow long-
term sustainability at reasonable cost to facili-
tate research that will develop novel therapies
and diagnostic tools more efﬁciently and
quickly.
TISSUE BIORESOURCE
The tissue bioresource comprises two parts:
In order to facilitate high-throughput analysis of
biomarkers suitable for real-world clinical use, we
are constructing a tissue microarray (TMA) contain-
ing tumour samples from 750 known patients with
MPM. This is being constructed using formalin-
ﬁxed parafﬁn-embedded blocks with high-quality
anonymised-linked clinical data from cases that
have been diagnosed in hospitals across the UK in
the last 10 years. A minimum of four cores is taken
from each block to allow for tumour heterogeneity.
The TMA is being constructed in modular form so
that researchers can readily test their biomarkers of
choice on a selection of cases and then validate
their results on a separate large cohort. TMA slides
will be scanned into a digital pathology imaging
system to facilitate remote web-based viewing and
scoring of stained TMA sections. In order to
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preserve antigenicity cut slides will be dipped in parafﬁn wax
and stored at 4°C.
In parallel, we are prospectively collecting tissue, blood,
pleural ﬂuid and data from 300 patients across the UK with con-
ﬁrmed or suspected MPM undergoing routine diagnostic or
treatment procedures as shown in ﬁgure 1.
Multiple surgical tissue samples are being collected from each
patient and stored in a manner suitable for histological, prote-
omic, genomic or transcriptomic analysis at a later date. Prior to
archiving, each tissue sample is being reviewed centrally by our
histopathologist for size, percentage tumour nuclei and percent-
age necrosis so that researchers can select those samples most
suited to their project goals. In addition, blood is stored as
serum, plasma and buffy coat fractions along with matching
pleural ﬂuid (cell pellets and supernatant) when available. When
processed, all samples are stored under strictly controlled condi-
tions at −80°C at Fisher BioServices, UK, ready for shipment to
researchers on request. To facilitate sample collection we
provide standardised collection kits containing a complete set of
prebarcoded blood, pleural ﬂuid and tissue sample pots. Once
samples are processed according to MesobanK SOPs, they are
scanned into the centralised secure database which links each
sample and patient code without the need for sample containers
to be labelled with patient identifying information. Details of
MesobanK SOPs are available at http://www.mesobank.com. In
addition to our planned collection, bespoke sample collection
can be arranged on request.
Anonymised-linked clinical data for every prospective and
retrospective case are entered into a purpose-built database.
Although retrospective data collection for TMA samples is fre-
quently challenging to obtain, a minimum data set of commonly
recorded clinical information has been deﬁned (see online sup-
plementary appendix 1). The local clinical data set will be sup-
plemented by data drawn from the National Cancer Registration
Service (NCRS). This will ensure that the MesobanK TMA will
be the world’s most comprehensive resource of this type. To
ensure comprehensive and accurate data accompanies every pro-
spective sample, the NCRS will provide MesobanK with six
monthly data updates about subsequent treatment episodes and
survival.
CELL LINES
Another important hindrance to clinical research into MPM is a
lack of high-quality cell lines for in vitro studies. Many of the
existing lines were generated a number of years ago and no
longer represent good models for their original tumours. To
address this, in collaboration with Professor Marion
MacFarlane, Medical Research Council (MRC) Toxicology Unit,
University of Leicester and Dr Zsuzanna Tabi, University of
Cardiff, 26 new MPM cell lines have been generated for
MesobanK.
Primary tumour surgical tissue or pleural ﬂuid cells are grown
in Roswell Park Memorial Institute (RPMI) medium supplemen-
ted either with 10% fetal calf serum (FBS) or with 2% FBS, 2%
hydrocortisone, epidermal growth factor and heparin depending
upon the source laboratory. Cells have been passaged between
six and nine times to expand their number and remove ﬁbro-
blast contamination. The original tumour subtype, patient
gender and age are provided along with cell line immunoreactiv-
ity to mesothelin, calretinin and cytokeratins and in some cases
5T4, podoplanin and HBME1. Neither karyotyping nor short
tandem repeat PCR has been performed, but when provided by
user laboratories we will make this available. Depending upon
the source laboratory of each cell line further characterisation
has been performed on selected lines including human leucocyte
antigen typing and scanning electron microscopy. End users will
be asked to monitor the characteristics and behaviour of each
cell line over time in order to ensure that they remain true to
the original cultures details of which are available from the
central MesobanK distribution laboratory (SJM, Cambridge
Institute for Medical Research).
Figure 1 Flow diagram for patient samples and data. QC, quality control.
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GOVERNANCE
MesobanK follows the ‘Guiding Principles’ laid out by the
National Cancer Research Institute Confederation of Cancer
Biobanks4 and the MRC Operational and Ethical Guidelines on
‘Human Tissue and Biological Materials for Use in Research’.5
The Health Research Authority Conﬁdentiality Advisory Group
has granted MesobanK permission to extract data from the
NCRS using exemption from Section 251 of the Health and
Social Care Act 2001 for TMA samples of patients who are
deceased without having to ask living relatives for consent. For
prospective specimen collection ethical approval has been
granted to set up MesobanK as a Research Tissue Bank. The
Human Tissue Authority (HTA) and National Research Ethics
Service have agreed a position whereby National Health Service
(NHS) research ethics committees can give generic ethical
approval for a research tissue bank’s arrangements for collec-
tion, storage and release of tissue, providing the tissue in the
bank is stored on HTA-licensed premises. This approval can
extend to speciﬁc projects receiving non-identiﬁable tissue from
the bank. The tissue does not then need to be stored on
HTA-licensed premises nor does it need project speciﬁc external
ethical approval for research being undertaken in the UK. Prior
to contributing any samples, all patients are requested to give
informed consent for blood and tissue banking in accordance
with the Human Tissue Act (2004)/Human Tissue (Scotland)
Act 2006. Each patient is provided with detailed written infor-
mation about the nature of the tissue bank along with any risk,
discomfort or potential beneﬁt derived from participation. A
tiered consent process is in place with participants able to
consent to which sample types they are prepared to donate. All
subjects are asked to consent to collection of data about their
subsequent clinical care and outcome. The patient information
sheet and consent form make speciﬁc reference to collection of
data from the NCRS and other sources. All subjects are made
aware of their right to withdraw their consent for the use of
their tissue/blood or clinical information at any time. The prin-
ciples of good clinical practice are adhered to throughout the
biobanking process.
A steering committee with an independent chair has been
appointed to oversee the tissue bank. A project manager sup-
ported by a project team, both based at Papworth Hospital
NHS Foundation Trust, assumes day-to-day responsibility for
MesobanK and oversees all operational aspects of the
bioresource.
ACCESS TO SAMPLES
Requests for access to samples and data can be made to
MesobanK. Applications are reviewed by the project team who
can call upon a Research Advisory Board comprising scientiﬁc,
clinical and lay members to advise upon the ethical and scien-
tiﬁc integrity of projects, when necessary. Subject to these
caveats and tissue availability, samples will be made available
whenever possible. Researchers will be encouraged to make
ﬁndings obtained using MesobanK samples freely available to
other researchers. Although MesobanK is a not-for-proﬁt
project, a cost-recovery model is in place to recover direct and
indirect costs incurred in collection, processing, quality control
and curation. All fees are used to offset future running costs of
MesobanK in order to ensure long-term sustainability.
In summary, we have established a international bioresource
to assist the biomedical community tackle this devastating
cancer. Although retrospective and prospective tissue collection
is not yet complete, we are already in a position to supply
researchers with these valuable samples. Finally, we wish to
thank all those patients and relatives who have so kindly made
this possible.
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